Skip to main content
. 2014 Nov 18;29(2):662–670. doi: 10.1096/fj.14-255398

Figure 5.

Figure 5.

FMOD affects the NF-κB pathway. A) Western blot for IKK1, IKK2, TRAF2, and β-actin in HMVECs treated with FMOD (3 nM). B) Western blot for IKBα and β-actin in HMVECs treated with FMOD (3 nM). C) MCP-1 ELISA on HMVECs treated with 1 μM NF-κB inhibitor (MG-132), with or without FMOD (3 nM). D) Luminescence analyzed luciferase secretion after HMVECs were transfected with MetLucNF-κB and treated with FMOD (3 nM). E) Quantification of MCP-1 level secreted by ECs after treatment with QNZ (10 ng/ml) or anti-FMOD (0.2 mg/ml). All experiments were repeated at least 3 times. **P < 0.001; ***P < 0.0001.